RecruitingPhase 4NCT06513039

Evaluation of Erythropoietin on Alveolar Ridge Preservation

Evaluation of Erythropoietin on Alveolar Ridge Preservation: (A Randomized Controlled Clinical Trial With Histomorphometric Assessment)


Sponsor

Ain Shams University

Enrollment

15 participants

Start Date

Jan 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

regenerative materials would help in decreasing post-extraction resorption in sites indicated for placement of a conventional bridge or prosthetically driven implant. Erythropoietin (EPO) is a growth factor that promotes angiogenesis and bone regeneration by stimulating osteoblastic differentiation and by inhibiting osteoclastic resorption. Post-extraction alveolar ridge resorption creates morphological and volumetric changes. These changes can be considered of clinical value that may threaten the placement of a conventional bridge or an implant-supported crown. Atwood et al. \[1\] in a cephalometric study categorized factors influencing the rate of alveolar ridge resorption into 4 types: anatomic, metabolic, functional, and prosthetic. As stated by Tan et al. \[2\] in a systematic review of alveolar hard and soft tissue dimensional changes in humans post-extraction, they found that alveolar ridge resorption occurs to a greater extent in a horizontal direction than vertical. Therefore, alveolar ridge preservation (ARP) procedures were introduced in an attempt to prevent hard and soft tissue dimensional changes following extraction.


Eligibility

Min Age: 18 YearsMax Age: 40 Years

Inclusion Criteria6

  • Age range (18-40).
  • Hopeless teeth indicated for extraction such as root fractures, caries, internal root resorption, external root resorption, endodontic failures.
  • Systemically free patients using Cornell Medical Index-Health Questionnaire \[36\].
  • Patients diagnosed with intact surrounding alveolar bone (socket type I) \[37\].
  • Maxillary anterior teeth and/or premolars indicated for extraction.
  • Enough zone of keratinized tissue (≥2 mm).

Exclusion Criteria4

  • Smokers
  • Occlusal trauma at the site of the graft
  • Pregnancy and lactation
  • Bad compliance with the plaque control instructions following initial therapy.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGErythropoietin carried on chitosan carrier

Patient will have extraction of teeth and placement of Erythropoietin carried on chitosan carrier for six months to enhance bone healing

OTHERchitosan carrier

inert scaffold agent


Locations(1)

Faculty of Dentistry Ain Shams University

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06513039


Related Trials